IL23A and palmoplantar pustulosis: Meanwhile, the results of a randomized controlled study evaluating the efficacy of ustekinumab (UST), an anti-IL12/23(p40) antibody that acts on both the IL-12-Th1 and IL-23-Th17 cell axes, for PPP have shown that the effects of UST on skin lesions are limited [12].